What is Helix?
Helix operates at the critical intersection of clinical care, research, and genomics, offering an end-to-end platform designed to facilitate the integration of genomic data into clinical practice. The company empowers health systems, life sciences organizations, and payers to advance genomic research and clinical applications. Leveraging one of the world's largest CLIA/CAP next-generation sequencing labs and its proprietary Exome+ assay, Helix supports comprehensive population genomics initiatives. These include patient recruitment and engagement, clinically actionable disease screening, return of genomic results, and foundational and translational research. The company's mission is to make genomic information more accessible and actionable for improving health outcomes.
How much funding has Helix raised?
Helix has raised a total of $383M across 4 funding rounds:
Series A
$100M
Series B
$200M
Grant
$33M
Series C
$50M
Series A (2015): $100M with participation from Warburg Pincus, Sutter Hill Ventures, and Illumina
Series B (2018): $200M led by Warburg Pincus, Mayo Clinic, Illumina, Draper Fisher Jurvetson (DFJ), Sutter Hill Ventures, and Kleiner Perkins Caufield & Byers
Grant (2020): $33M supported by U.S. National Institutes of Health (NIH)
Series C (2021): $50M featuring Warburg Pincus, Temasek, Kleiner Perkins, Mayo Clinic, and DFJ Growth
Key Investors in Helix
Warburg Pincus
Warburg Pincus is a leading global private equity firm specializing in growth investing, known for its extensive experience in supporting management teams to build long-term value across various market cycles and industries.
Temasek
Temasek is a global investment company headquartered in Singapore, operating as a generational investor focused on making a difference with a long-term perspective.
Kleiner Perkins
Kleiner Perkins is a venture capital firm that invests in early and growth-stage technology and life science companies, providing capital and operational support from seed through IPO.
What's next for Helix?
With its substantial enterprise-level backing and recent strategic investment, Helix is well-positioned for accelerated growth and innovation. The company's focus on integrating genomic data into clinical care, supported by its robust sequencing capabilities, suggests a strategic push towards broader adoption of its platform by healthcare providers and research institutions. Future developments are likely to center on expanding its clinical utility, enhancing its research offerings, and potentially forging new partnerships within the life sciences and healthcare ecosystems. The ongoing investment signals strong confidence in Helix's model for advancing population genomics and its potential to reshape personalized medicine.
See full Helix company page
